Following is background information and a Q & A released by the Pharming/Genzyme LLC on important issues concerning clinical trials

Leiden, the Netherlands/Cambridge, Mass., October 14, 1998—Pharming Group N.V. (Easdaq: PHAR), the Netherlands biopharmaceutical company, and the American biotechnology company

Human Gene Therapy 9:1609-1616 (July 20, 1998) Mary Ann Liebert, Inc. Adenovirus-Mediated Transfer of Human Acid Maltase Gene Reduces Glycogen

National Institutes of Health Paul Plotz, M.D., Nina Raben, M.D., Ph.D. Nina Raben, M.D., Ph.D., NIH Research Chemist, visited the

Human Molecular Genetics, January 1998 “Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease” by A.